Dennis Slamon

Dennis Slamon is the discoverer of HER2 amplification as a breast cancer driver and led the development of trastuzumab (Herceptin), one of the first successful targeted cancer therapies. His understanding of breast cancer molecular subtyping including triple-negative disease has shaped the field for decades. He contributed to characterizing the biology of TNBC and to development of novel therapeutic approaches including CDK4/6 inhibitors across breast cancer subtypes. His career exemplifies the translation of basic molecular discoveries into transformative clinical therapies.